321 related articles for article (PubMed ID: 19468270)
21. Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia.
Ichikawa H; Tanabe K; Mizushima H; Hayashi Y; Mizutani S; Ishii E; Hongo T; Kikuchi A; Satake M
Br J Haematol; 2006 Nov; 135(3):336-47. PubMed ID: 16989659
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.
Jung HA; Maeng CH; Park S; Kim SJ; Kim K; Jang JH; Jung CW
Anticancer Res; 2014 Feb; 34(2):1037-45. PubMed ID: 24511052
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.
Zhai Y; Wang Q; Ji L; Ren H; Dong Y; Yang F; Yin Y; Liang Z; Wang Q; Liu W; Mei Y; Zhang L; Li Y
Cancer Med; 2023 Dec; 12(24):21592-21604. PubMed ID: 38062912
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and management of core-binding factor leukemias.
Seiter K
Curr Hematol Rep; 2003 Jan; 2(1):78-85. PubMed ID: 12901158
[TBL] [Abstract][Full Text] [Related]
25. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.
Ustun C; Marcucci G
Curr Opin Hematol; 2015 Mar; 22(2):85-91. PubMed ID: 25635758
[TBL] [Abstract][Full Text] [Related]
26. Granulocytic sarcoma of Core-binding Factor (CBF) acute myeloid leukemia mimicking pancreatic cancer.
Schäfer HS; Becker H; Schmitt-Gräff A; Lübbert M
Leuk Res; 2008 Sep; 32(9):1472-5. PubMed ID: 18456326
[TBL] [Abstract][Full Text] [Related]
27. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
Paschka P; Marcucci G; Ruppert AS; Mrózek K; Chen H; Kittles RA; Vukosavljevic T; Perrotti D; Vardiman JW; Carroll AJ; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2006 Aug; 24(24):3904-11. PubMed ID: 16921041
[TBL] [Abstract][Full Text] [Related]
28. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.
Duployez N; Willekens C; Marceau-Renaut A; Boudry-Labis E; Preudhomme C
Expert Rev Hematol; 2015 Feb; 8(1):43-56. PubMed ID: 25348871
[TBL] [Abstract][Full Text] [Related]
29. New agents in post-remission therapy.
Stone RM
Best Pract Res Clin Haematol; 2010 Dec; 23(4):475-9. PubMed ID: 21130410
[TBL] [Abstract][Full Text] [Related]
30. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
Hasegawa D; Tawa A; Tomizawa D; Watanabe T; Saito AM; Kudo K; Taga T; Iwamoto S; Shimada A; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Miyachi H; Horibe K; Nakahata T; Adachi S
Pediatr Blood Cancer; 2020 Dec; 67(12):e28692. PubMed ID: 32886449
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.
Krauter J; Wagner K; Schäfer I; Marschalek R; Meyer C; Heil G; Schaich M; Ehninger G; Niederwieser D; Krahl R; Büchner T; Sauerland C; Schlegelberger B; Döhner K; Döhner H; Schlenk RF; Ganser A
J Clin Oncol; 2009 Jun; 27(18):3000-6. PubMed ID: 19380453
[TBL] [Abstract][Full Text] [Related]
32. [Clinical and cytogenetic features and their influencing factors of core binding factor acute myeloid leukemia].
Li W; Mi YC; Liu BC; Zhou CL; Lin D; Wang HJ; Liu XP; Li QH; Bian SG; Wang JX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Oct; 33(5):517-24. PubMed ID: 22338135
[TBL] [Abstract][Full Text] [Related]
33. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; von Neuhoff C; Sander A; Schrauder A; Teigler-Schlegel A; Stary J; Corbacioglu S; Reinhardt D
Blood; 2011 Nov; 118(20):5409-15. PubMed ID: 21948298
[TBL] [Abstract][Full Text] [Related]
34. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
Baldus CD; Bullinger L
Semin Oncol; 2008 Aug; 35(4):356-64. PubMed ID: 18692686
[TBL] [Abstract][Full Text] [Related]
35. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
Wang B; Zhang J; Hua X; Li H; Wang Z; Yang B
Sci Rep; 2020 Jan; 10(1):685. PubMed ID: 31959790
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
37. Complementing mutations in core binding factor leukemias: from mouse models to clinical applications.
Müller AM; Duque J; Shizuru JA; Lübbert M
Oncogene; 2008 Oct; 27(44):5759-73. PubMed ID: 18604246
[TBL] [Abstract][Full Text] [Related]
38. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.
Darwish C; Farina K; Tremblay D
Blood Rev; 2023 Nov; 62():101117. PubMed ID: 37524647
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of acute myeloid leukemia and its impact on treatment.
Frankfurt O; Licht JD; Tallman MS
Curr Opin Oncol; 2007 Nov; 19(6):635-49. PubMed ID: 17906465
[TBL] [Abstract][Full Text] [Related]
40. Core binding factor acute myeloid leukemia.
Marcucci G
Clin Adv Hematol Oncol; 2006 May; 4(5):339-41. PubMed ID: 16728942
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
